SNAI2 encodes a zinc finger transcriptional repressor that orchestrates epithelial-to-mesenchymal transition (EMT) and controls cellular plasticity across multiple tissues 1. As a sequence-specific DNA-binding protein, SNAI2 represses E-cadherin transcription and regulates genes controlling cell adhesion and migration, facilitating epithelial phenotypic switching 1. In cancer biology, SNAI2 is particularly significant: it promotes glioblastoma growth and invasion, with expression correlating to histologic grade and invasiveness 2. SNAI2 functions as a central hub in EGFR-mediated local invasion networks in head and neck cancer, where it coordinates with integrin and laminin signaling 3. In pancreatic cancer, GREM1-mediated BMP inhibition suppresses SNAI2 expression to maintain epithelial populations and restrict mesenchymal conversion 4. FOSL1 establishes super-enhancers at the SNAI2 locus to drive metastatic cancer stemness programs in head and neck tumors 5. Beyond cancer, SNAI2 mediates endothelial-to-mesenchymal transition in glaucomatous trabecular meshwork fibrosis 6 and represents a pathogenic intersection between cancer and cardiovascular disease 7. Therapeutically, SNAI2 induction by histone deacetylase inhibitors can sensitize colon cancer cells to platinum chemotherapy 8, suggesting SNAI2 modulation as a potential treatment strategy.